Email: cspc@cspc.cn
Media
News Center
Aug. 11
2026
VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL TRIAL OF SYS6063 FOR THE TREATMENT OF RELAPSED, REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS OFFICIALLY INITIATED AT THE FI
Aug. 10
VOLUNTARY ANNOUNCEMENT - SYS6037 INJECTION (MPOX MRNA VACCINE) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Aug. 04
VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION FOR ANBENITAMAB (KN026) AND DOCETAXEL FOR INJECTION (ALBUMIN-BOUND) (HB1801) FOR NEOADJUVANT TREATMENT ACCEPTED BY
Aug. 03
VOLUNTARY ANNOUNCEMENT - PHASE IB/II CLINICAL TRIAL OF SYS 6090 INJECTION FOR THE TREATMENT OF COLORECTAL CANCER OFFICIALLY INITIATED AT THE FIRST CENTRE IN CHI
Jul. 31
VOLUNTARY ANNOUNCEMENT - RECOMBINANT RESPIRATORY SYNCYTIAL VIRUS VACCINE (SYS6057) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SYS6041 AS A COMBINATION THERAPY FOR THE TREATMENT OF RECURRENT OVARIAN CANCER OFFICIALLY INITIATED AT THE F
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
